Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Total Debt (2016 - 2026)

Ocular Therapeutix has reported Total Debt over the past 14 years, most recently at $72.1 million for Q1 2026.

  • For Q1 2026, Total Debt rose 4.13% year-over-year to $72.1 million; the TTM value through Mar 2026 reached $72.1 million, up 4.13%, while the annual FY2025 figure was $71.3 million, 4.13% up from the prior year.
  • Total Debt for Q1 2026 was $72.1 million at Ocular Therapeutix, up from $71.3 million in the prior quarter.
  • Over five years, Total Debt peaked at $72.1 million in Q1 2026 and troughed at $23.3 million in Q2 2023.
  • A 5-year average of $53.1 million and a median of $66.5 million in 2024 define the central range for Total Debt.
  • Biggest five-year swings in Total Debt: dropped 7.26% in 2023 and later soared 188.08% in 2024.
  • Year by year, Total Debt stood at $25.3 million in 2022, then skyrocketed by 160.47% to $65.8 million in 2023, then rose by 4.13% to $68.5 million in 2024, then increased by 4.13% to $71.3 million in 2025, then rose by 1.02% to $72.1 million in 2026.
  • Business Quant data shows Total Debt for OCUL at $72.1 million in Q1 2026, $71.3 million in Q4 2025, and $70.6 million in Q3 2025.